Clinical UpdatesDrug News

Bristol-Myers Squibb Co and Johnson & Johnson plan to jointly develop experimental treatments for hepatitis C in a market worth… »   

Three leading senators are inquiring into drugmaker Pfizer Inc’s efforts to limit the sale of generic versions of its Lipitor… »   

Researchers from Mount Sinai School of Medicine, have identified the pattern of cell signaling induced by antipsychotic drugs in a… »   

As the “recycling plant” of the cell, the proteasome regulates vitally important functions. When it is inhibited, the cell chokes… »   

Timed to coincide with European Antibiotics Awareness Day on Friday 18th November, the UK’s Department of Health is urging hospitals… »   

Pfizer Inc, the world’s largest drug maker, aims to push sales of its Prevenar vaccine for children beyond large Chinese… »   

A human monoclonal antibody developed by MassBiologics of the University of Massachusetts Medical School (UMMS) given to patients with chronic… »   

It may take a breakthrough treatment for Alzheimer’s disease to match the $130 billion lifetime sales record of Pfizer’s Lipitor,… »   

President Barack Obama signed an executive order on Monday to address an escalating shortage of life-saving medicines, his newest effort… »   

As Americans line up for flu shots, they should consider that the vaccines may be far less effective than thought,… »   

Europe will strictly limit the amount of information that drugmakers can supply to the public on prescription-only medicines and retain… »   

Pfizer said on Tuesday it had filed a patent infringement suit in a Moscow court against Teva Pharmaceutical to prevent… »   

At a cafe on 18th Street in San Francisco, David sipped coffee and talked about the regimen of daily H.I.V.… »   

A Phase III study of Afinitor® (everolimus) tablets* in patients with non-cancerous kidney tumors, or angiomyolipomas, associated with tuberous sclerosis… »   

Pfizer Inc has not decided how it might divest its nutrition or animal health businesses, the drugmaker’s chief financial officer… »